Enfortumab vedotin plus pembrolizumab was associated with improvements in response, disease control, and survival when compared to chemotherapy. Results of a meta-analysis suggest that enfortumab ...

Cisplatin-based combination chemotherapy remains the standard of care for locally advanced or metastatic urothelial cancer (la/mUC); however, toxicity is substantial, responses are rarely durable, and ...

Two Sealed Airtight Medical Vials Against Bright Background Front View. Enfortumab vedotin plus pembrolizumab improved survival outcomes, when compared to chemotherapy, in patients with previously ...

– Confirmatory trial found PADCEV plus pembrolizumab nearly doubled median overall survival compared to standard of care platinum-based chemotherapy – "Today's FDA approval represents a paradigm ...

Seagen Inc. SGEN along with Japanese partner Astellas Pharma, Inc announced that the European Medicines Agency (“EMA”) has accepted the marketing authorization application (“MAA”) for their ...

The Food and Drug Administration (FDA) has granted Priority Review to enfortumab vedotin-ejfv (Padcev ™) in combination with pembrolizumab (Keytruda ®) as a neoadjuvant treatment and then continued ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive ...

An interdisciplinary research team has published new findings that indicate which patients with advanced urothelial carcinoma could benefit in particular from the new targeted therapy with the ...

Please provide your email address to receive an email when new articles are posted on . The combination of enfortumab vedotin and pembrolizumab conferred high rates of durable responses among ...

IMvigor130: A randomized, phase III study evaluating first-line (1L) atezolizumab (atezo) as monotherapy and in combination with platinum-based chemotherapy (chemo) in patients (pts) with locally ...

Please provide your email address to receive an email when new articles are posted on . In cohort 2 of the single-arm phase 2 EV-201 study, enfortumab vedotin conferred durable responses with ...